An allosteric inhibitor against the therapy-resistant mutant forms of EGFR in non-small cell lung cancer
Ciric To, Tyler S. Beyett, Jaebong Jang, William W. Feng, Magda Bahcall, Heidi M. Haikala, Bo Hee Shin, David E. Heppner, Jaimin K. Rana, Brittaney A. Leeper, Kara M. Soroko, Michael J. Poitras, Prafulla C. Gokhale, Yoshihisa Kobayashi, Kamal Wahid, Kari J. Kurppa, Thomas W. Gero, Michael D. Cameron, Atsuko Ogino, Mierzhati Mushajiang, Chunxiao Xu, Yanxi Zhang, David A. Scott, Michael J. Eck, Nathanael S. Gray, Pasi A. Jänne
Topics & Concepts
T790MEpidermal growth factor receptorAllosteric regulationEGFR inhibitorsLung cancerCancer researchErlotinibMutantGefitinibTyrosine kinaseCombination therapyTyrosine-kinase inhibitorDrug resistanceMutationTargeted therapyMedicineCancerPharmacologyBiologyReceptorOncologyInternal medicineGeneticsGeneLung Cancer Treatments and MutationsHER2/EGFR in Cancer ResearchColorectal Cancer Treatments and Studies